サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1301160

ヘルスケア受託開発・製造機関の市場規模、シェア、動向分析レポート：サービス別（受託開発、受託製造）、地域別、セグメント予測、2023年～2030年

Healthcare Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Services (Contract Development, Contract Manufacturing), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.46円
ヘルスケア受託開発・製造機関の市場規模、シェア、動向分析レポート：サービス別（受託開発、受託製造）、地域別、セグメント予測、2023年～2030年
出版日: 2023年06月29日
発行: Grand View Research
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ヘルスケア受託開発・製造機関市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のヘルスケア受託開発・製造機関市場規模は2030年までに4,710億米ドルに達する見込みです。

同市場は2023年から2030年にかけてCAGR 9.5％で拡大すると予測されています。同市場は、研究開発費の増加とアウトソーシング動向の高まりにより、有利な成長が見込まれています。

ヘルスケア受託開発・製造機関（CDMO）は、さまざまな製薬業界にアウトソーシングサービスを契約ベースで提供しています。製薬企業によるアウトソーシングの増加、製薬業界の拡大、CDMOによる運営費および資本費の削減支援は、予測期間における市場成長を促進すると予想される主な要因の一部です。

また、製薬企業や医療機器企業に対する厳しいスケジュール遵守へのプレッシャーの高まりが、CDMOへの開発・製造活動のアウトソーシング需要を高めています。さらに、新興諸国における医療機器需要の増加により、様々な企業が医療機器の受託開発・製造のための研究開発活動に重点を移しつつあります。過去10年間、いくつかの製薬会社は、自社の新規イノベーションのプレフォーミュレーションや開発・製造を支援するため、CMO、CRO、CDMOに目を向けてきました。アウトソーシングは高成長市場であり、ほとんどの支出は初期開発に集中しています。

新薬パイプラインの約75%は中堅・中小のバイオ製薬会社によるものです。これらの企業は利益率が高く、コスト削減を目指すヘルスケア・プロバイダーの格好のターゲットとなっています。そのため、これらの企業にとっては、自社のインフラ構築に投資する代わりに、専門知識と必要な設備を備えた第三者機関にサービスを委託することが利益につながります。いくつかの製薬会社は、分子開発を最適化するためにアウトソーシング・サービスを求めています。例えば、米国を拠点とするバイオテクノロジー企業Remedium Bioは2023年3月、ベルギーを拠点とするCDMOであるExotheraと、Remediumのリード遺伝子治療薬候補である変形性関節症治療薬AAV2-FGF18の生産規模を拡大するための提携契約を締結しました。

しかし、物流コストの増加、医療機関が直面するシリアル化の問題、知的財産権（IP）侵害の脅威は、予測期間中、ヘルスケア受託開発・製造機関の市場成長を抑制すると予想されます。

ヘルスケア受託開発・製造機関市場レポートハイライト

  • 製薬企業および医療機器企業別製造サービスのアウトソーシング増加により、2022年の市場収益シェアは製造受託部門が73.5%で市場を独占しました。
  • 低分子化合物の受託開発サブセグメント別では、新規治療薬のパイプラインの増加により、前臨床/セグメントが予測期間中に10.4%という最高のCAGRで成長すると予想されます。
  • 北米は2022年に40.9%という最大の売上シェアを獲得し、ヘルスケア受託開発・製造機関市場を独占しました。同地域のシェアが高いのは、同地域、特に米国で活発に機能しているCROやCMOが多数存在することが主因です。
  • アジア太平洋地域は予測期間中に10.4%という最も速いCAGRで成長すると予測されています。同地域は、アジアのCROおよびCMOが提供する低コストの開発・製造受託サービスにより、有利なCAGRが予測されます。

目次

第1章 調査手法と範囲

  • 市場セグメンテーションと範囲
    • セグメントの定義
    • サービス
  • 地域の範囲
  • 推定・予測のタイムライン
  • 目的
  • 調査手法
  • 情報調達
    • 購入したデータベース
    • GVRの内部データベース
    • 二次情報
    • 1次調査
  • 情報またはデータ分析
    • データ分析モデル
  • 市場の形成と検証
  • モデル詳細
    • 商品フロー分析
    • 親市場分析
  • 二次情報のリスト
  • 略語のリスト

第2章 エグゼクティブサマリー

  • 市場の見通し
  • セグメントの見通し
  • 競合考察

第3章 ヘルスケアCDMO市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助的な市場見通し
  • サービス別の製品パイプライン分析
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ヘルスケアCDMO市場分析ツール
    • 業界分析- ポーターズ
    • PESTEL分析
    • COVID-19の影響分析
    • 主要取引と戦略的提携の分析

第4章 ヘルスケアCDMO市場：サービスの推定・動向分析

  • ヘルスケアCDMO市場、サービス別：セグメントダッシュボード
  • ヘルスケアCDMO市場、サービス別：変動分析
    • 受託開発
    • 受託製造

第5章 ヘルスケアCDMO市場：地域推定・動向分析

  • 地域市場シェア分析、2022年および2030年
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 北米
    • 市場推計・予測、2018年から2030年（収益、100万米ドル）
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
    • オランダ
    • ベルギー
  • アジア太平洋地域
    • 日本
    • インド
    • 中国
    • 韓国
    • オーストラリア
    • タイ
    • マレーシア
    • ニュージーランド
    • シンガポール
    • フィリピン
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • チリ
  • MEA
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート
    • イスラエル

第6章 競合情勢

  • 市場参入企業の分類
    • イノベーター
    • マーケットリーダー
    • 新興プレイヤー
    • 企業の市場シェア分析、2022年
  • 企業プロファイル
    • Catalent Inc.
    • Lonza
    • Recipharm AB
    • Siegfried Holding AG
    • Thermo Fisher Scientific, Inc
    • Labcorp Drug Development
    • Jabil Inc
    • Syngene International Limited
    • IQVIA Inc.
    • Almac Group
    • Ajinomoto Bio-Pharma
    • Adare Pharma Solutions
    • Alcami Corporation
    • Vetter Pharma International

第7章 KoLの解説/推奨事項

図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Healthcare CDMO Market, By Region 2018 - 2030 (USD Billion)
  • Table 4 Global Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 5 North America Healthcare CDMO Market, By Country, 2018 - 2030 (USD Billion)
  • Table 6 North America Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 7 U.S. Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 8 Canada Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 9 Europe Healthcare CDMO Market, By Country, 2018 - 2030 (USD Billion)
  • Table 10 Europe Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 11 UK Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 12 Germany Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 13 France Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 14 Italy Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 15 Spain Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 16 Netherlands Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 17 Belgium Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 18 Denmark Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 19 Norway Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 20 Sweden Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 21 Asia Pacific Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 22 China Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 23 Japan Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 24 India Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 25 Australia Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 26 South Korea Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 27 Malaysia Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 28 New Zealand Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 29 Singapore Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 30 Philippines Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 31 Thailand Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 32 Latin America Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 33 Brazil Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 34 Mexico Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 35 Argentina Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 36 Colombia Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 37 Chile Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 38 Middle East & Africa Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 39 South Africa Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 40 Saudi Arabia Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 41 UAE Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 42 Israel Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)
  • Table 43 Kuwait Healthcare CDMO Market, By Services, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modelling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Primary research pattern
  • Fig. 8 Primary interviews in North America
  • Fig. 9 Primary interviews in Europe
  • Fig. 10 Primary interviews in Asia Pacific
  • Fig. 11 Primary interviews in Latin America
  • Fig. 12 Primary interviews in MEA
  • Fig. 13 Market Snapshot
  • Fig. 14 Segment Snapshot
  • Fig. 15 Segment Snapshot
  • Fig. 16 Competitive Landscape Snapshot
  • Fig. 17 Healthcare CDMO market segmentation
  • Fig. 18 Parent market outlook (2022)
  • Fig. 19 Related/ancillary market outlook (2022)
  • Fig. 20 Market driver relevance analysis (Current & future impact)
  • Fig. 21 Current shared services and outsourcing usage levels
  • Fig. 22 Market restraint relevance analysis (Current & future impact)
  • Fig. 23 Porter's five forces analysis
  • Fig. 24 SWOT analysis, by a factor (political & legal, economic and technological)
  • Fig. 25 Healthcare CDMO Market Services outlook: Segment dashboard
  • Fig. 26 Healthcare CDMO: Services movement analysis
  • Fig. 27 Contract Development market, 2018 - 2030 (USD Million)
  • Fig. 28 Small Molecule market, 2018 - 2030 (USD Million)
  • Fig. 29 Preclinical market, 2018 - 2030 (USD Million)
  • Fig. 30 Bioanalysis and DMPK studies market, 2018 - 2030 (USD Million)
  • Fig. 31 Toxicology Testing market, 2018 - 2030 (USD Million)
  • Fig. 32 Other Preclinical Services market, 2018 - 2030 (USD Million)
  • Fig. 33 Clinical market, 2018 - 2030 (USD Million)
  • Fig. 34 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 35 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 36 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 37 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 38 Laboratory Services market, 2018 - 2030 (USD Million)
  • Fig. 39 Bioanalytical Services market, 2018 - 2030 (USD Million)
  • Fig. 40 Analytical Services market, 2018 - 2030 (USD Million)
  • Fig. 41 Large Molecule market, 2018 - 2030 (USD Million)
  • Fig. 42 Cell Line Development market, 2018 - 2030 (USD Million)
  • Fig. 43 Process Development market, 2018 - 2030 (USD Million)
  • Fig. 44 Upstream market, 2018 - 2030 (USD Million)
  • Fig. 45 Microbial market, 2018 - 2030 (USD Million)
  • Fig. 46 Mammalian market, 2018 - 2030 (USD Million)
  • Fig. 47 Others market, 2018 - 2030 (USD Million)
  • Fig. 48 Downstream market, 2018 - 2030 (USD Million)
  • Fig. 49 MABs market, 2018 - 2030 (USD Million)
  • Fig. 50 Recombinant proteins market, 2018 - 2030 (USD Million)
  • Fig. 51 Others market, 2018 - 2030 (USD Million)
  • Fig. 52 Others market, 2018 - 2030 (USD Million)
  • Fig. 53 Contract Manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 54 Small Molecule market, 2018 - 2030 (USD Million)
  • Fig. 55 Large Molecule market, 2018 - 2030 (USD Million)
  • Fig. 56 MABs market, 2018 - 2030 (USD Million)
  • Fig. 57 Recombinant Proteins market, 2018 - 2030 (USD Million)
  • Fig. 58 Others market, 2018 - 2030 (USD Million)
  • Fig. 59 High Potency API market, 2018 - 2030 (USD Million)
  • Fig. 60 Finished Dose Formulations market, 2018 - 2030 (USD Million)
  • Fig. 61 Solid Dose Formulation market, 2018 - 2030 (USD Million)
  • Fig. 62 Liquid Dose Formulation market, 2018 - 2030 (USD Million)
  • Fig. 63 Injectable Dose Formulation market, 2018 - 2030 (USD Million)
  • Fig. 64 Medical Devices market, 2018 - 2030 (USD Million)
  • Fig. 65 Class I market, 2018 - 2030 (USD Million)
  • Fig. 66 Class II market, 2018 - 2030 (USD Million)
  • Fig. 67 Class III market, 2018 - 2030 (USD Million)
  • Fig. 68 Regional marketplace: Segment dashboard
  • Fig. 69 Regional outlook, 2022 & 2030
  • Fig. 70 North America market, 2018 - 2030 (USD Million)
  • Fig. 71 U.S. market, 2018 - 2030 (USD Million)
  • Fig. 72 Canada market, 2018 - 2030 (USD Million)
  • Fig. 73 Europe market, 2018 - 2030 (USD Million)
  • Fig. 74 Germany market, 2018 - 2030 (USD Million)
  • Fig. 75 UK market, 2018 - 2030 (USD Million)
  • Fig. 76 France market, 2018 - 2030 (USD Million)
  • Fig. 77 Italy market, 2018 - 2030 (USD Million)
  • Fig. 78 Spain market, 2018 - 2030 (USD Million)
  • Fig. 79 Denmark market, 2018 - 2030(USD Million)
  • Fig. 80 Sweden market, 2018 - 2030 (USD Million)
  • Fig. 81 Norway market, 2018 - 2030 (USD Million)
  • Fig. 82 Netherlands market, 2018 - 2030 (USD Million)
  • Fig. 83 Belgium market, 2018 - 2030 (USD Million)
  • Fig. 84 Asia Pacific market, 2018 - 2030 (USD Million)
  • Fig. 85 China market, 2018 - 2030 (USD Million)
  • Fig. 86 Japan market, 2018 - 2030 (USD Million)
  • Fig. 87 India market, 2018 - 2030 (USD Million)
  • Fig. 88 Australia market, 2018 - 2030 (USD Million)
  • Fig. 89 South Korea market, 2018 - 2030 (USD Million)
  • Fig. 90 Thailand market, 2018 - 2030 (USD Million)
  • Fig. 91 Malaysia market, 2018 - 2030 (USD Million)
  • Fig. 92 New Zealand market, 2018 - 2030 (USD Million)
  • Fig. 93 Singapore market, 2018 - 2030 (USD Million)
  • Fig. 94 Philippines market, 2018 - 2030 (USD Million)
  • Fig. 95 Latin America market, 2018 - 2030 (USD Million)
  • Fig. 96 Brazil market, 2018 - 2030 (USD Million)
  • Fig. 97 Mexico market, 2018 - 2030 (USD Million)
  • Fig. 98 Argentina market, 2018 - 2030 (USD Million)
  • Fig. 99 Colombia market, 2018 - 2030 (USD Million)
  • Fig. 100 Chile market, 2018 - 2030 (USD Million)
  • Fig. 101 Middle East & Africa market, 2018 - 2030 (USD Million)
  • Fig. 102 South Africa market, 2018 - 2030 (USD Million)
  • Fig. 103 Saudi Arabia market, 2018 - 2030 (USD Million)
  • Fig. 104 UAE market, 2018 - 2030 (USD Million)
  • Fig. 105 Kuwait market, 2018 - 2030 (USD Million)
  • Fig. 106 Israel market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68038-438-3

Healthcare Contract Development And Manufacturing Organization Market Growth & Trends

The global healthcare contract development and manufacturing organization market size is expected to reach USD 471.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 9.5% from 2023 to 2030. The market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trends.

Healthcare Contract Development and Manufacturing Organization (CDMO) provide outsourcing services to various pharmaceutical industries on a contract basis. An increase in outsourcing by pharmaceutical companies, expansions in the pharmaceutical industry, and the support of CDMOs in reducing operational and capital expenses are some of the major factors anticipated to propel the market growth in the forecast period.

In addition, growing pressure on pharmaceutical and medical device companies to follow stringent timelines has increased the demand for outsourcing development and manufacturing activities to CDMOs. Further, due to the increasing demand for medical devices in emerging countries, various companies are shifting their focus on research and development activities for medical device contract development and manufacturing. Over the past 10 years, several pharmaceutical companies have turned to CMOs, CROs, and CDMOs to assist in preformulation and development & manufacturing of their novel innovations. Outsourcing is a high growth market and most spending is focused on early development.

Around 75% of new drug pipelines come from small and midsized biopharmaceutical companies. These companies have high profit margins, which make them easy targets for healthcare providers who are trying to reduce cost. Thus, instead of investing in establishing their own infrastructure, it is profitable for these companies to outsource services to third-party organizations who have expertise and the required equipment. Several pharmaceutical companies are seeking outsourced services for optimizing the development of their molecule. For instance, in March 2023, Remedium Bio, a U.S.-based biotechnology company, entered in a collaboration agreement with Exothera, a Belgium-based CDMO, to scale up the production of Remedium's lead gene therapy drug candidate, AAV2-FGF18 in the treatment of osteoarthritis.

However, increasing logistic costs, serialization issues faced by healthcare organizations, and the threat of infringement of Intellectual Property (IP) rights are anticipated to restrain the market growth for healthcare contract development & manufacturing organization over the forecast period.

Healthcare Contract Development And Manufacturing Organization Market Report Highlights

  • The contract manufacturing segment dominated the market with a revenue share of 73.5% in 2022 due to increase in the outsourcing of manufacturing services by pharmaceutical and medical device companies
  • By small molecule contract development sub-segment, the preclinical/segment is expected to register the highest CAGR of 10.4% in the forecast period due to the rising pipeline of novel therapeutics
  • North America dominated the healthcare contract development and manufacturing organization market with the largest revenue share of 40.9% in 2022. High shares of the region are majorly due to the presence of a large number of actively functioning CROs and CMOs in the region, especially across the U.S.
  • The Asia Pacific is projected to witness the fastest CAGR of 10.4% during the forecast period. The region is anticipated to witness a lucrative CAGR owing to the low-cost contract development and manufacturing services offered by Asian CROs and CMOs

Table of Contents

Chapter 1. Research Methodology And Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
    • 1.1.2. Services
  • 1.2. Regional Scope
  • 1.3. Estimates And Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
    • 1.9.2. Parent Market Analysis
  • 1.10. List Of Secondary Sources
  • 1.11. List Of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Healthcare CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Product Pipeline Analysis, by Service
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
      • 3.3.1.1. Increasing Outsourcing Services By Pharmaceutical Companies
      • 3.3.1.2. Rising Investment In R&D
      • 3.3.1.3. Growing Pharmaceutical Industry
      • 3.3.1.4. Increasing Demand For One-Stop-Shop CDMOs
    • 3.3.2. Market Restraint Analysis
      • 3.3.2.1. Compliance Issues While Outsourcing
      • 3.3.2.2. Changing Scenarios In Developing Countries
      • 3.3.2.3. Regulatory And Legal Compliance
  • 3.4. Healthcare CDMO Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier Power
      • 3.4.1.2. Buyer Power
      • 3.4.1.3. Substitution Threat
      • 3.4.1.4. Threat Of New Entrant
      • 3.4.1.5. Competitive Rivalry
    • 3.4.2. PESTEL Analysis
    • 3.4.3. COVID-19 Impact Analysis
    • 3.4.4. Major Deals & Strategic Alliances Analysis
      • 3.4.4.1. Mergers & Acquisitions
      • 3.4.4.2. Geographic Expansions
      • 3.4.4.3. Partnerships
      • 3.4.4.4. Launch
      • 3.4.4.5. Collaborations

Chapter 4. Healthcare CDMO Market: Services Estimates & Trend Analysis

  • 4.1. Healthcare CDMO Market, By Services: Segment Dashboard
  • 4.2. Healthcare CDMO Market, By Services: Movement Analysis
  • 4.3. Healthcare CDMO Market Estimates & Forecasts, By Services, 2018 - 2030
    • 4.3.1. Contract Development
      • 4.3.1.1. Contract Development Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2. Small Molecule
      • 4.3.1.2.1. Small Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2. Preclinical
      • 4.3.1.2.2.1. Preclinical Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2.2. Bioanalysis and DMPK studies
      • 4.3.1.2.2.2.1. Bioanalysis and DMPK studies Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2.3. Toxicology Testing
      • 4.3.1.2.2.3.1. Toxicology Testing Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.2.4. Other Preclinical Services
      • 4.3.1.2.2.4.1. Other Preclinical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3. Clinical
      • 4.3.1.2.3.1. Clinical Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.2. Phase I
      • 4.3.1.2.3.2.1. Phase I Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.3. Phase II
      • 4.3.1.2.3.3.1. Phase II Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.4. Phase III
      • 4.3.1.2.3.4.1. Phase III Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.3.5. Phase IV
      • 4.3.1.2.3.5.1. Phase IV Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.4. Laboratory Services
      • 4.3.1.2.4.1. Laboratory Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.4.2. Bioanalytical Services
      • 4.3.1.2.4.2.1. Bioanalytical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.2.4.3. Analytical Services
      • 4.3.1.2.4.3.1. Analytical Services Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3. Large Molecule
      • 4.3.1.3.1. Large Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.2. Cell line development
      • 4.3.1.3.2.1. Cell line development Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3. Process Development
      • 4.3.1.3.3.1. Process Development Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2. Upstream
      • 4.3.1.3.3.2.1. Upstream Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2.2. Microbial
      • 4.3.1.3.3.2.2.1. Microbial Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2.3. Mammalian
      • 4.3.1.3.3.2.3.1. Mammalian Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.2.4. Others
      • 4.3.1.3.3.2.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3. Downstream
      • 4.3.1.3.3.3.1. Downstream Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3.2. MABs
      • 4.3.1.3.3.3.2.1. MABs Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3.3. Recombinant Proteins
      • 4.3.1.3.3.3.3.1. Recombinant Proteins Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.1.3.3.3.4. Others
      • 4.3.1.3.3.3.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.2. Contract Manufacturing
      • 4.3.2.1. Contract Manufacturing Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.2. Small Molecule
      • 4.3.2.2.1. Small Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3. Large Molecule
      • 4.3.2.3.1. Large Molecule Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3.2. MABs
      • 4.3.2.3.2.1. MABs Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3.3. Recombinant Proteins
      • 4.3.2.3.3.1. Recombinant Proteins Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.3.4. Others
      • 4.3.2.3.4.1. Others Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.4. High Potency API
      • 4.3.2.4.1. High Potency API Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5. Finished Dose Formulations
      • 4.3.2.5.1. Finished Dose Formulations Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5.2. Solid Dose Formulation
      • 4.3.2.5.2.1. Solid Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5.3. Liquid Dose Formulation
      • 4.3.2.5.3.1. Liquid Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.5.4. Injectable Dose Formulation
      • 4.3.2.5.4.1. Injectable Dose Formulation Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6. Medical Device
      • 4.3.2.6.1. Medical Device Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6.2. Class I
      • 4.3.2.6.2.1. Class I Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6.3. Class II
      • 4.3.2.6.3.1. Class II Healthcare CDMO Market, 2018 to 2030 (USD Million)
      • 4.3.2.6.4. Class III
      • 4.3.2.6.4.1. Class III Healthcare CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Healthcare CDMO Market: Regional Estimates & Trend Analysis

  • 5.1. Regional Market Share Analysis, 2022 & 2030
  • 5.2. Regional Market Dashboard
  • 5.3. Global Regional Market Snapshot
  • 5.4. North America
    • 5.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. U.S.
      • 5.4.2.1. Key Country Dynamics
      • 5.4.2.2. Competitive Scenario
      • 5.4.2.3. Regulatory Framework
      • 5.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
    • 5.4.3. Canada
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Competitive Scenario
      • 5.4.3.3. Regulatory Framework
      • 5.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
  • 5.5. Europe
    • 5.5.1. UK
      • 5.5.1.1. Key Country Dynamics
      • 5.5.1.2. Competitive Scenario
      • 5.5.1.3. Regulatory Framework
      • 5.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
    • 5.5.2. Germany
      • 5.5.2.1. Key Country Dynamics
      • 5.5.2.2. Competitive Scenario
      • 5.5.2.3. Regulatory Framework
      • 5.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
    • 5.5.3. France
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Competitive Scenario
      • 5.5.3.3. Regulatory Framework
      • 5.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
    • 5.5.4. Italy
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Competitive Scenario
      • 5.5.4.3. Regulatory Framework
      • 5.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
    • 5.5.5. Spain
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Competitive Scenario
      • 5.5.5.3. Regulatory Framework
      • 5.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
    • 5.5.6. Denmark
      • 5.5.6.1. Key Country Dynamics
      • 5.5.6.2. Competitive Scenario
      • 5.5.6.3. Regulatory Framework
      • 5.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
    • 5.5.7. Sweden
      • 5.5.7.1. Key Country Dynamics
      • 5.5.7.2. Competitive Scenario
      • 5.5.7.3. Regulatory Framework
      • 5.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
    • 5.5.8. Norway
      • 5.5.8.1. Key Country Dynamics
      • 5.5.8.2. Competitive Scenario
      • 5.5.8.3. Regulatory Framework
      • 5.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
    • 5.5.9. Netherlands
      • 5.5.9.1. Key Country Dynamics
      • 5.5.9.2. Competitive Scenario
      • 5.5.9.3. Regulatory Framework
      • 5.5.9.4. Netherlands Market Estimates and Forecasts, 2018 - 2030
    • 5.5.10. Belgium
      • 5.5.10.1. Key Country Dynamics
      • 5.5.10.2. Competitive Scenario
      • 5.5.10.3. Regulatory Framework
      • 5.5.10.4. Belgium Market Estimates and Forecasts, 2018 - 2030
  • 5.6. Asia Pacific
    • 5.6.1. Japan
      • 5.6.1.1. Key Country Dynamics
      • 5.6.1.2. Competitive Scenario
      • 5.6.1.3. Regulatory Framework
      • 5.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
    • 5.6.2. India
      • 5.6.2.1. Key Country Dynamics
      • 5.6.2.2. Competitive Scenario
      • 5.6.2.3. Regulatory Framework
      • 5.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
    • 5.6.3. China
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Competitive Scenario
      • 5.6.3.3. Regulatory Framework
      • 5.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
    • 5.6.4. South Korea
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Competitive Scenario
      • 5.6.4.3. Regulatory Framework
      • 5.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
    • 5.6.5. Australia
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Competitive Scenario
      • 5.6.5.3. Regulatory Framework
      • 5.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
    • 5.6.6. Thailand
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Competitive Scenario
      • 5.6.6.3. Regulatory Framework
      • 5.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
    • 5.6.7. Malaysia
      • 5.6.7.1. Key Country Dynamics
      • 5.6.7.2. Competitive Scenario
      • 5.6.7.3. Regulatory Framework
      • 5.6.7.4. Malaysia Market Estimates and Forecasts, 2018 - 2030
    • 5.6.8. New Zealand
      • 5.6.8.1. Key Country Dynamics
      • 5.6.8.2. Competitive Scenario
      • 5.6.8.3. Regulatory Framework
      • 5.6.8.4. New Zealand Market Estimates and Forecasts, 2018 - 2030
    • 5.6.9. Singapore
      • 5.6.9.1. Key Country Dynamics
      • 5.6.9.2. Competitive Scenario
      • 5.6.9.3. Regulatory Framework
      • 5.6.9.4. Singapore Market Estimates and Forecasts, 2018 - 2030
    • 5.6.10. Philippines
      • 5.6.10.1. Key Country Dynamics
      • 5.6.10.2. Competitive Scenario
      • 5.6.10.3. Regulatory Framework
      • 5.6.10.4. Philippines Market Estimates and Forecasts, 2018 - 2030
  • 5.7. Latin America
    • 5.7.1. Brazil
      • 5.7.1.1. Key Country Dynamics
      • 5.7.1.2. Competitive Scenario
      • 5.7.1.3. Regulatory Framework
      • 5.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
    • 5.7.2. Mexico
      • 5.7.2.1. Key Country Dynamics
      • 5.7.2.2. Competitive Scenario
      • 5.7.2.3. Regulatory Framework
      • 5.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
    • 5.7.3. Argentina
      • 5.7.3.1. Key Country Dynamics
      • 5.7.3.2. Competitive Scenario
      • 5.7.3.3. Regulatory Framework
      • 5.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
    • 5.7.4. Colombia
      • 5.7.4.1. Key Country Dynamics
      • 5.7.4.2. Competitive Scenario
      • 5.7.4.3. Regulatory Framework
      • 5.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030
    • 5.7.5. Chile
      • 5.7.5.1. Key Country Dynamics
      • 5.7.5.2. Competitive Scenario
      • 5.7.5.3. Regulatory Framework
      • 5.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030
  • 5.8. MEA
    • 5.8.1. South Africa
      • 5.8.1.1. Key Country Dynamics
      • 5.8.1.2. Competitive Scenario
      • 5.8.1.3. Regulatory Framework
      • 5.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
    • 5.8.2. Saudi Arabia
      • 5.8.2.1. Key Country Dynamics
      • 5.8.2.2. Competitive Scenario
      • 5.8.2.3. Regulatory Framework
      • 5.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
    • 5.8.3. UAE
      • 5.8.3.1. Key Country Dynamics
      • 5.8.3.2. Competitive Scenario
      • 5.8.3.3. Regulatory Framework
      • 5.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
    • 5.8.4. Kuwait
      • 5.8.4.1. Key Country Dynamics
      • 5.8.4.2. Competitive Scenario
      • 5.8.4.3. Regulatory Framework
      • 5.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030
    • 5.8.5. Israel
      • 5.8.5.1. Key Country Dynamics
      • 5.8.5.2. Competitive Scenario
      • 5.8.5.3. Regulatory Framework
      • 5.8.5.4. Israel Market Estimates and Forecasts, 2018 - 2030

Chapter 6. Competitive Landscape

  • 6.1. Market Participant Categorization
    • 6.1.1. Innovators
    • 6.1.2. Market Leaders
    • 6.1.3. Emerging Players
    • 6.1.4. Company Market Share Analysis, 2022
  • 6.2. Company Profiles
    • 6.2.1. Catalent Inc.
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Service Benchmarking
      • 6.2.1.4. Strategic Initiatives
    • 6.2.2. Lonza
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Service Benchmarking
      • 6.2.2.4. Strategic Initiatives
    • 6.2.3. Recipharm AB
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Performance
      • 6.2.3.3. Service Benchmarking
      • 6.2.3.4. Strategic Initiatives
    • 6.2.4. Siegfried Holding AG
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Financial Performance
      • 6.2.4.3. Service Benchmarking
      • 6.2.4.4. Strategic Initiatives
    • 6.2.5. Thermo Fisher Scientific, Inc
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Performance
      • 6.2.5.3. Service Benchmarking
      • 6.2.5.4. Strategic Initiatives
    • 6.2.6. Labcorp Drug Development
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Performance
      • 6.2.6.3. Service Benchmarking
      • 6.2.6.4. Strategic Initiatives
    • 6.2.7. Jabil Inc
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Performance
      • 6.2.7.3. Service Benchmarking
      • 6.2.7.4. Strategic Initiatives
    • 6.2.8. Syngene International Limited
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Financial Performance
      • 6.2.8.3. Service Benchmarking
      • 6.2.8.4. Strategic Initiatives
    • 6.2.9. IQVIA Inc.
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Financial Performance
      • 6.2.9.3. Service Benchmarking
      • 6.2.9.4. Strategic Initiatives
    • 6.2.10. Almac Group
      • 6.2.10.1. Company Overview
      • 6.2.10.2. Financial Performance
      • 6.2.10.3. Service Benchmarking
      • 6.2.10.4. Strategic Initiatives
    • 6.2.11. Ajinomoto Bio-Pharma
      • 6.2.11.1. Company Overview
      • 6.2.11.2. Financial Performance
      • 6.2.11.3. Service Benchmarking
      • 6.2.11.4. Strategic Initiatives
    • 6.2.12. Adare Pharma Solutions
      • 6.2.12.1. Company Overview
      • 6.2.12.2. Financial Performance
      • 6.2.12.3. Service Benchmarking
      • 6.2.12.4. Strategic Initiatives
    • 6.2.13. Alcami Corporation
      • 6.2.13.1. Company Overview
      • 6.2.13.2. Financial Performance
      • 6.2.13.3. Service Benchmarking
      • 6.2.13.4. Strategic Initiatives
    • 6.2.14. Vetter Pharma International
      • 6.2.14.1. Company Overview
      • 6.2.14.2. Financial Performance
      • 6.2.14.3. Service Benchmarking
      • 6.2.14.4. Strategic Initiatives

Chapter 7. KoL Commentary/Recommendations